Sight Diagnostics Expands to Canada through a Distribution Partnership with Inter Medico

Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, today announced a distribution partnership with Inter Medico to expand into Canada. Sight has received Health Canada approval to provide Sight OLO® analyzers to laboratories, ultimately enabling fast, accurate, 5-part differential blood testing across the country, especially in small rural and remote laboratories.

The Canadian in-vitro diagnostics market is expected to have a compound annual growth rate of 5.2% over the next 4 years. One factor responsible for this growth is the need for faster, more accurate testing solutions that can help providers make quick and informed treatment decisions. CBC is one of the most commonly ordered blood tests because it offers insight into the status of a patient’s overall health and is particularly helpful in determining triage and care decisions for COVID-19 patients.

“As COVID-19 cases continue to rise in Canada, we want to ensure that all laboratories, including those in small rural and remote locations have access to all the technology and information they need to best care for their patients,” stated Dan Lichtman, CEO of Inter Medico. “We chose to work with Sight because we’ve seen how its analyzer has improved patient care in hospitals and labs in other countries and have seen firsthand how easy it is to implement and use.”

Through its partnership with Inter Medico, Sight will transform the way labs in Canada traditionally run. Sight OLO leverages a patented method of “digitizing” blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence -- providing results in minutes with only two drops of blood.

Additionally, Sight seeks to extend Sight OLO’s impact in different clinical settings via Inter Medico’s industry ties with strategic partners. “As one of Inter Medico’s partners, we’re excited to be among the first providers to bring this new technology to psychiatry patients treated with Clozapine,” remarked Geoffrey Johnson, AA Pharma’s Director, Sales & Marketing. “There is significant underutilization in this patient population because of barriers to treatment, including the requirement for regular blood monitoring. We look forward to enabling health care providers to make quick and informed treatment decisions with fast and accurate CBC results from OLO.”

Since raising $71M in its Series D last year, Sight has grown both externally and internally, with close to 3 times increase in Sight OLO’s installation worldwide and more than 50% increase in headcount. During the peak of the pandemic, OLO was deployed by Sheba Tel Hashomer Medical Center in Israel in a dedicated lab to process blood samples from COVID-19 patients. Most recently, Oxford University Hospitals implemented OLO inside the emergency department to support the CURIAL-Rapide validation study to more quickly and accurately diagnose COVID-19 patients and determine who needs more immediate attention based on their CBC results.

“We’re thrilled to be partnering with well established regional partners to continue our mission in bringing decentralized blood testing to key markets across the world,” said Yossi Pollak, CEO and Cofounder of Sight Diagnostics. “Last year, Sight signed dozens of long-term strategic agreements across the world to deploy more than 1,000 analyzers, and we’re looking forward to building on this momentum with Inter Medico in Canada.”

*This press release is intended for audiences in Canada. In Canada, Sight OLO received a Medical Device License from Health Canada for use in laboratories; it has not yet been cleared for point-of-care use. Outside of Canada and the United States, Sight OLO is CE Marked and listed in the Australian Register of Therapeutic Goods with a point of care indication. For full indications for use and safety information please refer to the Quality and Compliance page at www.sightdx.com.

About Sight Diagnostics

Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. Sight OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, ParasightTM, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at www.SightDX.com.

About Inter Medico

Inter Medico specializes in providing leading edge instrumentation and reagent solutions to Canadian customers. We are proud of the success we have achieved over the past 40 years based on our dedicated service and support. Our organization consists of a matrix of front-line support through our bilingual customer support team, a coast-to-coast network of Account Managers and Field Service Engineers. Our technical support team is ready to answer any questions related to our reagents and instrumentation through our bilingual 24-hour, 7 day a week 1-800 hotline. Learn more at www.Inter-Medico.com.

About AA Pharma

AA Pharma is a Canadian company focused on legacy pharmaceutical products. Legacy pharmaceuticals are drug products with well-established efficacy and safety profiles and years of real-world experience. AA Pharma manufacturers over 80 treatments in a range of therapeutic areas. Learn more at www.aapharma.ca.

Contact Information

Riley Munks

Media Contact

VSC for Sight Diagnostics

sight@vsc.co